Philips Spotlights New Cardiology Solutions and Unveils Ultrasound Technology at European Society of Cardiology Congress 2014

— Innovative cardiology solutions help deliver better care for more patients, respond to biggest challenges facing cardiologists

ANDOVER, Mass., Aug. 29, 2014 /PRNewswire/ – Royal Philips (NYSE: PHG AEX: PHIA) today announced its presence at the European Society of Cardiology (ESC) Congress 2014, where the company …

Read More

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

— No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study

OSAKA, Japan, Aug. 29, 2014 /PRNewswire/ — Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of …

Read More

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

LONDON, Aug. 23, 2014 /PRNewswire/ — ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.1 Triumeq is ViiV Healthcare’s first dolutegravir-based fixed-dose …

Read More

Amerigen Pharmaceuticals Ltd. Announces that its Chinese Subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has Received Chinese FDA (CFDA) Approval and has Subsequently Launched its Generic Mecobalamin 0.5 mg Tablets into the China Domestic Market

LYNDHURST, N.J., Aug. 20, 2014 /PRNewswire/ — Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic market. Under the terms of a …

Read More

Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study

— Company To Pursue Next Stage of Development

REDWOOD CITY, California, Aug. 15, 2014  /PRNewswire/ — Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared …

Read More

Accenture and Philips announce proof of concept app to show how ALS patients could gain greater control of their lives through brain, voice and eye commands

— Software connects Emotiv Insight Brainware to wearable display that allows wearers to command Philips Hue lighting, SmartTV and Lifeline products

ANDOVER, Mass. and NEW YORK, Aug. 5, 2014 /PRNewswire/ — Royal Philips (NYSE: PHG; AEX: PHIA) and Accenture  (NYSE: ACN) today announced that …

Read More